BACKGROUND. Thrombotic thrombocytopenic purpura is an uncommon disease with a high mortality rate even with current treatment. The cause of the syndrome and its optimal treatment are unknown. Although both plasma exchange and plasma infusion have been useful treatments, it is not clear which is superior. In this report we describe a prospective randomized trial comparing plasma exchange with plasma infusion for the treatment of thrombotic thrombocytopenic purpura. METHODS. One hundred two patients with thrombotic thrombocytopenic purpura were randomly assigned to receive either plasma exchange or plasma infusion with fresh-frozen plasma on seven of the first nine days after entry into the trial. The total volume of plasma received by patients undergoing plasma exchange was three times that received by patients undergoing plasma infusion. All the patients also received aspirin and dipyridamole. The outcomes in the two groups were compared at the end of the first treatment cycle (day 9) and after six months. RESULTS. At the end of the first treatment cycle patients receiving plasma exchange had a higher rate of response as defined by an increase in the platelet count (24 of 51 patients) than those who received plasma infusion (13 of 51, P = 0.025). Of the 51 patients treated with plasma exchange, 2 died, whereas 8 of the 51 patients who received plasma infusion died (P = 0.035). After six months the outcome in the plasma-exchange group was still superior, with a response observed in 40 of 51 patients, whereas 25 of 51 patients in the plasma-infusion group responded (P = 0.002). Eleven patients in the plasma-exchange group died, as did 19 patients in the plasma-infusion group (P = 0.036). The overall mortality was 29 percent. CONCLUSIONS. Plasma exchange is more effective than plasma infusion in the treatment of thrombotic thrombocytopenic purpura.
Source Information
Department of Medicine, University of Ottawa, Ont., Canada.
This article has been cited by other articles:
Sadler, J. E.
(2008). Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood
112: 11-18
[Abstract][Full Text]
CROWTHER, M. A., GEORGE, J. N.
(2008). Thrombotic thrombocytopenic purpura: 2008 Update. Cleveland Clinic Journal of Medicine
75: 369-375
[Abstract][Full Text]
Lammle, B., Kremer Hovinga, J. A., George, J. N.
(2008). Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease. haematol
93: 172-177
[Full Text]
Desch, K. C., Motto, D. G.
(2007). Thrombotic Thrombocytopenic Purpura in Humans and Mice. Arterioscler. Thromb. Vasc. Bio.
27: 1901-1908
[Abstract][Full Text]
Hunt, B.J., Tueger, S., Pattison, J., Cavenagh, J., D'Cruz, D.P.
(2007). Microangiopathic haemolytic anaemia secondary to lupus nephritis: an important differential diagnosis of thrombotic thrombocytopenic purpura. Lupus
16: 358-362
[Abstract]
George, J. N.
(2007). Evaluation and Management of Patients With Thrombotic Thrombocytopenic Purpura. J Intensive Care Med
22: 82-91
[Abstract]
Stanworth, S. J.
(2007). The Evidence-Based Use of FFP and Cryoprecipitate for Abnormalities of Coagulation Tests and Clinical Coagulopathy. ASH Education Book
2007: 179-186
[Abstract][Full Text]
Matzdorff, A. C., George, J. N.
(2006). Thrombotic Thrombocytopenic Purpura. NEJM
355: 630-630
[Full Text]
Nishi, H., Hanafusa, N., Kondo, Y., Nangaku, M., Sugawara, Y., Makuuchi, M., Noiri, E., Fujita, T.
(2006). Clinical Outcome of Thrombotic Microangiopathy after Living-Donor Liver Transplantation Treated with Plasma Exchange Therapy. CJASN
1: 811-819
[Abstract][Full Text]
Patschan, D., Witzke, O., Duhrsen, U., Erbel, R., Philipp, T., Herget-Rosenthal, S.
(2006). Acute myocardial infarction in thrombotic microangiopathies--clinical characteristics, risk factors and outcome. Nephrol Dial Transplant
21: 1549-1554
[Abstract][Full Text]
George, J. N.
(2006). Clinical practice. Thrombotic thrombocytopenic purpura.. NEJM
354: 1927-1935
[Full Text]
Banno, F., Kokame, K., Okuda, T., Honda, S., Miyata, S., Kato, H., Tomiyama, Y., Miyata, T.
(2006). Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood
107: 3161-3166
[Abstract][Full Text]
Anderson, P. J., Kokame, K., Sadler, J. E.
(2006). Zinc and Calcium Ions Cooperatively Modulate ADAMTS13 Activity. J. Biol. Chem.
281: 850-857
[Abstract][Full Text]
Perkins, R. M., Reynolds, J. C., Ahuja, T. S., Reid, T., Agodoa, L. Y., Bohen, E. M., Yuan, C. M., Abbott, K. C.
(2006). Thrombotic microangiopathy in United States long-term dialysis patients. Nephrol Dial Transplant
21: 191-196
[Abstract][Full Text]
Sadler, J. E.
(2006). Thrombotic Thrombocytopenic Purpura: A Moving Target. ASH Education Book
2006: 415-420
[Abstract][Full Text]
Zhou, W., Dong, L., Ginsburg, D., Bouhassira, E. E., Tsai, H.-M.
(2005). Enzymatically Active ADAMTS13 Variants Are Not Inhibited by Anti-ADAMTS13 Autoantibodies: A NOVEL THERAPEUTIC STRATEGY?. J. Biol. Chem.
280: 39934-39941
[Abstract][Full Text]
Rock, G., Anderson, D., Benny, B., Clark, W., Leblond, P., Sutton, D., Sternbach, M., Wells, G., Members of the Canadian Apheresis Group, , Canadian Association of Apheresis Nurses,
(2005). Treatment of Thrombotic Thrombocytopenic Purpura Using Solvent Detergent Treated Plasma.. ASH ANNUAL MEETING ABSTRACTS
106: 3989-3989
[Abstract]
George, J. N.
(2005). Controlling chronic TTP. Blood
106: 1896-1896
[Full Text]
Levy, G. G., Motto, D. G., Ginsburg, D.
(2005). ADAMTS13 turns 3. Blood
106: 11-17
[Abstract][Full Text]
Linenberger, M. L., Price, T. H.
(2005). Use of Cellular and Plasma Apheresis in the Critically Ill Patient: Part II: Clinical Indications and Applications. J Intensive Care Med
20: 88-103
[Abstract]
Ibernon, M., Moreso, F., Carreras, L., Carrera, M., Serrano, T., Rama, I., Bestard, O., Torras, J., Poveda, R., Grinyo, J. M.
(2005). Thrombotic thrombocytopenic purpura with severe large artery branch involvement. Nephrol Dial Transplant
20: 467-468
[Full Text]
Wolf, G.
(2004). Not known from ADAM(TS-13)--novel insights into the pathophysiology of thrombotic microangiopathies. Nephrol Dial Transplant
19: 1687-1693
[Full Text]
Zheng, X. L., Kaufman, R. M., Goodnough, L. T., Sadler, J. E.
(2004). Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood
103: 4043-4049
[Abstract][Full Text]
Zakarija, A., Bandarenko, N., Pandey, D. K., Auerbach, A., Raisch, D. W., Kim, B., Kwaan, H. C., McKoy, J. M., Schmitt, B. P., Davidson, C. J., Yarnold, P. R., Gorelick, P. B., Bennett, C. L.
(2004). Clopidogrel-Associated TTP: An Update of Pharmacovigilance Efforts Conducted by Independent Researchers, Pharmaceutical Suppliers, and the Food and Drug Administration. Stroke
35: 533-537
[Abstract][Full Text]
Boutron, I., Ravaud, P.
(2003). Premature Application of Trial Results to Clinical Practice. JAMA
290: 3072-3072
[Full Text]
Majerus, E. M., Zheng, X., Tuley, E. A., Sadler, J. E.
(2003). Cleavage of the ADAMTS13 Propeptide Is Not Required for Protease Activity. J. Biol. Chem.
278: 46643-46648
[Abstract][Full Text]
Clark, W. F., Garg, A. X., Blake, P. G., Rock, G. A., Heidenheim, A. P., Sackett, D. L.
(2003). Effect of Awareness of a Randomized Controlled Trial on Use of Experimental Therapy. JAMA
290: 1351-1355
[Abstract][Full Text]
Neumann, H P H, Salzmann, M, Bohnert-Iwan, B, Mannuelian, T, Skerka, C, Lenk, D, Bender, B U, Cybulla, M, Riegler, P, Konigsrainer, A, Neyer, U, Bock, A, Widmer, U, Male, D A, Franke, G, Zipfel, P F
(2003). Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J. Med. Genet.
40: 676-681
[Abstract][Full Text]
Zheng, X., Nishio, K., Majerus, E. M., Sadler, J. E.
(2003). Cleavage of von Willebrand Factor Requires the Spacer Domain of the Metalloprotease ADAMTS13. J. Biol. Chem.
278: 30136-30141
[Abstract][Full Text]
Vesely, S. K., George, J. N., Lammle, B., Studt, J.-D., Alberio, L., El-Harake, M. A., Raskob, G. E.
(2003). ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood
102: 60-68
[Abstract][Full Text]
Tsai, H.-M.
(2003). Advances in the Pathogenesis, Diagnosis, and Treatment of Thrombotic Thrombocytopenic Purpura. J. Am. Soc. Nephrol.
14: 1072-1081
[Abstract][Full Text]
Tsai, H.-M.
(2003). Platelet Activation and the Formation of the Platelet Plug: Deficiency of ADAMTS13 Causes Thrombotic Thrombocytopenic Purpura. Arterioscler. Thromb. Vasc. Bio.
23: 388-396
[Abstract][Full Text]
Zheng, X., Pallera, A. M., Goodnough, L. T., Sadler, J. E., Blinder, M. A.
(2003). Remission of Chronic Thrombotic Thrombocytopenic Purpura after Treatment with Cyclophosphamide and Rituximab. ANN INTERN MED
138: 105-108
[Abstract][Full Text]
George, J. N., Vesely, S. K.
(2003). Thrombotic Thrombocytopenic Purpura: From the Bench to the Bedside, but Not Yet to the Community. ANN INTERN MED
138: 152-153
[Full Text]
Tsai, H.-M., Lammle, B., Bianchi, V., Alberio, L., Furlan, M., Remuzzi, G., Galbusera, M., Mannucci, P. M.
(2002). Deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura. Blood
100: 3839-3842
[Full Text]
Plaimauer, B., Zimmermann, K., Volkel, D., Antoine, G., Kerschbaumer, R., Jenab, P., Furlan, M., Gerritsen, H., Lammle, B., Schwarz, H. P., Scheiflinger, F.
(2002). Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood
100: 3626-3632
[Abstract][Full Text]
DeLoughery, T. G.
(2002). Thrombocytopenia in Critical Care Patients. J Intensive Care Med
17: 267-282
[Abstract]
Ranzini, A. C., Chavez, M. R., Ghigliotty, B., Porcelli, M.
(2002). Thrombotic Thrombocytopenic Purpura and Human Immunodeficiency Virus Complicating Pregnancy. Obstet Gynecol
100: 1133-1136
[Abstract][Full Text]
Sadler, J. E.
(2002). A new name in thrombosis, ADAMTS13. Proc. Natl. Acad. Sci. USA
99: 11552-11554
[Full Text]
Ahmed, S, Siddiqui, R K, Siddiqui, A K, Zaidi, S A, Cervia, J
(2002). HIV associated thrombotic microangiopathy. Postgrad. Med. J.
78: 520-524
[Abstract][Full Text]
Moake, J. L.
(2002). Thrombotic Microangiopathies. NEJM
347: 589-600
[Full Text]
Tostivint, I., Mougenot, B., Flahault, A., Vigneau, C., Costa, M.-A., Haymann, J.-P., Sraer, J.-D., Rondeau, E.
(2002). Adult haemolytic and uraemic syndrome: causes and prognostic factors in the last decade. Nephrol Dial Transplant
17: 1228-1234
[Abstract][Full Text]
George, J. N., Sadler, J. E., Lammle, B.
(2002). Platelets: Thrombotic Thrombocytopenic Purpura. ASH Education Book
2002: 315-334
[Abstract][Full Text]
Kojouri, K., Vesely, S. K., George, J. N.
(2001). Quinine-Associated Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome: Frequency, Clinical Features, and Long-Term Outcomes. ANN INTERN MED
135: 1047-1051
[Abstract][Full Text]
Moore, J. C., Hayward, C. P. M., Warkentin, T. E., Kelton, J. G.
(2001). Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood
98: 1842-1846
[Abstract][Full Text]
YAMASAKI, S, TOMINAGA, M, KAWAKAMI, A, MIGITA, K, KAWABE, Y, IZUMINO, K, EGUCHI, K, TSUCHIYA, T, SHIMOKAWA, I
(2001). Polyarteritis nodosa complicated by thrombotic thrombocytopenic purpura. Ann Rheum Dis
60: 541-542
[Full Text]
Wallace, D J
(2001). Apheresis for lupus erythematosus: state of the art. Lupus
10: 193-196
[Abstract]
McCrae, K. R., Bussel, J. B., Mannucci, P. M., Remuzzi, G., Cines, D. B.
(2001). Platelets: An Update on Diagnosis and Management of Thrombocytopenic Disorders. ASH Education Book
2001: 282-305
[Abstract][Full Text]
Bennett, C. L., Connors, J. M., Carwile, J. M., Moake, J. L., Bell, W. R., Tarantolo, S. R., McCarthy, L. J., Sarode, R., Hatfield, A. J., Feldman, M. D., Davidson, C. J., Tsai, H.-M.
(2000). Thrombotic Thrombocytopenic Purpura Associated with Clopidogrel. NEJM
342: 1773-1777
[Abstract][Full Text]
Fakhouri, F., Vincent, F., Legendre, C.
(2000). Therapeutic Plasma Exchange. ANN INTERN MED
132: 760-760
[Full Text]
Clark, W. F., Rock, G., Shumak, K. A.
(2000). Therapeutic Plasma Exchange. ANN INTERN MED
132: 760-761
[Full Text]
Pogliani, E. M., Perseghin, P., Parma, M., Pioltelli, P., Corneo, G.
(2000). Defibrotide in Recurrent Thrombotic Thrombocytopenic Purpura. CLIN APPL THROMB HEMOST
6: 69-70
[Abstract]
Clark, W. F., Rock, G. A., Buskard, N., Shumak, K. H., LeBlond, P., Anderson, D., Sutton, D. M., for the Canadian Apheresis Group*,
(1999). Therapeutic Plasma Exchange: An Update from the Canadian Apheresis Group. ANN INTERN MED
131: 453-462
[Abstract][Full Text]
GALBUSERA, M., BENIGNI, A., PARIS, S., RUGGENENTI, P., ZOJA, C., ROSSI, C., REMUZZI, G.
(1999). Unrecognized Pattern of von Willebrand Factor Abnormalities in Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. J. Am. Soc. Nephrol.
10: 1234-1241
[Abstract][Full Text]
van der Plas, R. M., Schiphorst, M. E., Huizinga, E. G., Hene, R. J., Verdonck, L. F., Sixma, J. J., Fijnheer, R.
(1999). von Willebrand Factor Proteolysis Is Deficient in Classic, but not in Bone Marrow Transplantation-Associated, Thrombotic Thrombocytopenic Purpura. Blood
93: 3798-3802
[Abstract][Full Text]
KELLY, F. E, TREACHER, D. F, WILLIAMS, F. M K, HUNT, B. J, HOWARD, R. S
(1999). Coma in thrombotic thrombocytopenic purpura. J. Neurol. Neurosurg. Psychiatry
66: 689-690
[Full Text]
Mori, Y., Wada, H., Tamaki, S., Minami, N., Shiku, H., Ihara, T., Omine, M., Kakisita, E.
(1999). State-of-the-Art Review : Outcome of Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome in Japan. CLIN APPL THROMB HEMOST
5: 110-112
[Abstract]
Wallace, D J
(1999). Apheresis for lupus erythematosus. Lupus
8: 174-180
[Abstract]
Chen, D. K., Kim, J. S., Sutton, D. M. C.
(1999). Thrombotic Thrombocytopenic Purpura Associated With Ticlopidine Use: A Report of 3 Cases and Review of the Literature. Arch Intern Med
159: 311-314
[Abstract][Full Text]
Popovsky, M. A., Saidman, S. L.
(1998). Case 40-1998- A 49-Year-Old Woman with Thrombotic Thrombocytopenic Purpura and Severe Dyspnea during Plasmapheresis and Transfusion. NEJM
339: 2005-2012
[Full Text]
Tsai, H.-M., Lian, E. C.-Y.
(1998). Antibodies to von Willebrand Factor-Cleaving Protease in Acute Thrombotic Thrombocytopenic Purpura. NEJM
339: 1585-1594
[Abstract][Full Text]
Caramaschi, P, Riccetti, M M, Pasini, A F., Savarin, T, Biasi, D, Todeschini, G
(1998). Book Review: Systemic lupus erythematosus and thrombotic thrombocytopenic purpura. Report of three cases and review of the literature. Lupus
7: 37-41
[Abstract]
Furlan, M., Robles, R., Solenthaler, M., Wassmer, M., Sandoz, P., Lammle, B.
(1997). Deficient Activity of von Willebrand Factor-Cleaving Protease in Chronic Relapsing Thrombotic Thrombocytopenic Purpura. Blood
89: 3097-3103
[Abstract][Full Text]
Pineda, A. A., Vamvakas, E. C.
(1997). Applications of Therapeutic Apheresis in Patients with Malignant Disease. The Oncologist
2: 94-103
[Abstract][Full Text]
Eagle, K. A., Fallon, J. T.
(1994). Case 33-1994- A 41-Year-Old Woman with Thrombocytopenia, Anemia, and Sudden Death. NEJM
331: 661-667
[Full Text]
Wallace, D. J.
(1993). Plasmapheresis in Lupus. Lupus
2: 141-143
Tobias, J. D., Baker, D. K., Hurwitz, C. A.
(1992). Removal of Phenytoin by Plasmapheresis in a Patient with Thrombotic Thrombocytopenia Purpura. CLIN PEDIATR
31: 105-108
[Abstract]
Zheng, X., Chung, D., Takayama, T. K., Majerus, E. M., Sadler, J. E., Fujikawa, K.
(2001). Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic Purpura. J. Biol. Chem.
276: 41059-41063
[Abstract][Full Text]
Previous
